08 April 2019

Polyneuron raises CHF 22.5 million in a major Series A financing

Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing. The round was led by Sofinnova Partners and co-led by New Enterprise Associates (NEA), with the participation of existing investors.

VISCHER advises Polyneuron in this transaction. The team includes Matthias Staehelin (Partner, Corporate M&A), Moritz Jäggy (Managing Associate, Corporate M&A) and Sebastian Flückiger (Associate, Corporate M&A).

Share article on:

Service(s) included:

Get in touch with our authors and benefit from their expertise:

partner-Matthias-0

Matthias Staehelin

matthias.staehelin@vischer.com

+41 58 211 33 53

partner-Moritz-1

Moritz Jäggy

moritz.jaeggy@vischer.com

+41 58 211 32 33

Our
newsletter